Dr. Raje Discusses the Impact of bb2121in Myeloma

Noopur Raje, MD
Published: Tuesday, Sep 11, 2018



Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the impact of bb2121 and chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with multiple myeloma.

bb2121 could be an important addition to the armamentarium, Raje says. This therapy is resulting in stringent responses in patients with minimal residual disease (MRD)-negativity; this is unexpected to observe in a heavily pretreated patient population. Data from the phase I trial were very encouraging, with a median progression-free survival (PFS) of close to 1 year. The fact that there wasn’t much toxicity was also very reassuring, Raje adds.

Another exciting aspect of the data is the fact that median PFS for penta-refractory MRD-negative patients was longer than 17 months. The hope is that CAR T-cell therapy will cure myeloma. Raje says oncologists need to be a little more realistic, but that doesn’t minimize the results they’re seeing.


Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the impact of bb2121 and chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with multiple myeloma.

bb2121 could be an important addition to the armamentarium, Raje says. This therapy is resulting in stringent responses in patients with minimal residual disease (MRD)-negativity; this is unexpected to observe in a heavily pretreated patient population. Data from the phase I trial were very encouraging, with a median progression-free survival (PFS) of close to 1 year. The fact that there wasn’t much toxicity was also very reassuring, Raje adds.

Another exciting aspect of the data is the fact that median PFS for penta-refractory MRD-negative patients was longer than 17 months. The hope is that CAR T-cell therapy will cure myeloma. Raje says oncologists need to be a little more realistic, but that doesn’t minimize the results they’re seeing.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x